Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.92 |
| ▸ | CCR2 | P41597 | 9/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224917 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL2457372 | 0.95 | ROCK2 (0.98) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL1716387 | 0.95 | ROCK2 (0.98) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL2457485 | 0.94 | ROCK2 (0.96) | ROCK2ROCK1CCR2 | |
| SCHEMBL2804629 | 0.92 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL659846 | 0.92 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL659847 | 0.92 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL600089 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL5409256 | 0.87 | ROCK2 (0.83) | ROCK2ROCK1CCR2 | |
| SCHEMBL1717251 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-103254172-A | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | disclosed |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8410147-B2 | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410147-B2 | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| CN-101583361-B | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC | 2013-01-23 | — | — | CN | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158587-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| CN-101583361-A | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC (US) | 2009-11-18 | — | — | CN | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CCR2 162/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 3233/4885 |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885CCR2 2493/4885 |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CCR2 1028/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 3233/4885 |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CCR2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.